Your browser doesn't support javascript.
loading
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
Atkinson, Victoria; Sandhu, Shahneen; Hospers, Geke; Long, Georgina V; Aglietta, Massimo; Ferrucci, Pier F; Tulyte, Skaiste; Cappellini, Gian Carlo Antonini; Soriano, Virtudes; Ali, Sayed; Poprach, Alexandr; Cesas, Alvydas; Rodriguez-Abreu, Delvys; Lau, Mike; de Jong, Egbert; Legenne, Philippe; Stein, Dara; King, Brianna; van Thienen, Johannes V.
Affiliation
  • Atkinson V; Division of Cancer Services, Gallipoli Medical Research Foundation, The University of Queensland and Princess Alexandra Hospital, Brisbane, QLD.
  • Sandhu S; Department of Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Hospers G; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Long GV; Department of Medical Oncology, Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.
  • Aglietta M; Department of Oncology, Candiolo Cancer Center, University of Torino, Torino.
  • Ferrucci PF; Tumor Biotherapy Unit, European Institute of Oncology, IRCCS, Milano, Italy.
  • Tulyte S; Oncology Chemotherapy Department, Clinic of Internal Medicine, Oncology and Family Medicine, Vilnius University, Vilnius, Lithuania.
  • Cappellini GCA; IV Oncology Division, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Division of Cancer Services, Roma, Italy.
  • Soriano V; Medical Oncology, IVO - Servicio de Oncología, Valencia, Spain.
  • Ali S; Canberra Hospital, Garran, ACT, Australia (former).
  • Poprach A; Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Cesas A; Department of Oncology, Klaipeda University Hospital, Klaipeda, Lithuania.
  • Rodriguez-Abreu D; Medical Oncology Service, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain.
  • Lau M; Novartis Pharma AG, Basel, Switzerland.
  • de Jong E; Novartis Pharma AG, Basel, Switzerland.
  • Legenne P; Novartis Pharma AG, Basel, Switzerland.
  • Stein D; United BioSource Corporation: An Express Scripts Company, Montreal, QC, Canada (former).
  • King B; United BioSource Corporation: An Express Scripts Company, London, UK (former).
  • van Thienen JV; Department of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Melanoma Res ; 30(3): 261-267, 2020 06.
Article in En | MEDLINE | ID: mdl-31895752
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Oximes / Pyridones / Pyrimidinones / Skin Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Imidazoles / Melanoma Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Year: 2020 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Oximes / Pyridones / Pyrimidinones / Skin Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Imidazoles / Melanoma Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Year: 2020 Type: Article